Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Human and animal studies demonstrate that xylooligosaccharides (XOS) are a highly efficacious prebiotic ingredient that delivers benefits at a minimum level of 1.4 g/day (d), which is much lower than levels required by fructooligosaccharides (FOS, 5 g/d) or galactooligosaccharides (GOS, 8 g/d). XOS promotes gastrointestinal regularity and relieves diarrhea and constipation at 0.7 g/d and 1.4 g/d, respectively. Xylooligosaccharides may also reduce blood cholesterol and may improve glycemic control, although more data from clinical trials are needed to confirm preliminary findings.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sugar Pill | Placebo Comparator |
| |
| Xylooligosarcharide 2.8g | Active Comparator | Xylooligosarcharide 2.8grams |
|
| Xylooligosarcharide 1.4g | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo (Maltodextrin) | Dietary Supplement | Maltodextrin 505mg/capsule 8 capsules/day (4 with breakfast and 4 with dinner meal) |
|
| Measure | Description | Time Frame |
|---|---|---|
| The Effects of Xyloologosarcharide (XOS) on colonic bifidobacteria counts in healthy volunteers. | After a 2 weeks of run-in, 30 healthy volunteers were randomly assigned to take 1.4 grams/day of XOS, or 2.8 grams/day or placebo for 8 weeks. The bifidobarteria counts was assessed at screening, baseline, 4, 8 weeks on supplementation of XOS and after 2 week cessation of XOS. | 10 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Tolerance of XOS by healthy volunteers | The tolerance of XOS was assessed by questionnaires, adverse event logs with comparison with placebo control group | 10 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Heber, MD, PhD | UCLA Center for Human Nutrition | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UCLA Center for Human Nutriiton | Los Angeles | California | 90095 | United States | ||
| UCLA Center for Human Nutrition, David Geffen School of Medicine |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24513849 | Result | Finegold SM, Li Z, Summanen PH, Downes J, Thames G, Corbett K, Dowd S, Krak M, Heber D. Xylooligosaccharide increases bifidobacteria but not lactobacilli in human gut microbiota. Food Funct. 2014 Mar;5(3):436-45. doi: 10.1039/c3fo60348b. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C008315 | maltodextrin |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Xylooligosarcharide 1.4g | Dietary Supplement | 8 capsules (512 mg/capsule) 4 with breakfast and 4 with dinner meal |
|
|
| Xylooligosarcharide 2.8g | Dietary Supplement | 8 capsules (520 mg/capsule) to be taken in the morning and in the evening |
|
|
| Los Angeles |
| California |
| 90095 |
| United States |